PRESENTATIONNATION

PRESENTATIONNATION

Browse a growing database of presentations shared by companies worldwide.

Browse

Browse All
All Companies
Presentations
Infographics
Reports
Brochures

Company

Blog
About
Contact

Legal

Privacy Policy
Terms of Service

© 2026 Presentation Nation. All rights reserved.
Built in San Diego by Twenty6 Red, Inc.

HomepageDevon Energy CorporationDevon Energy_October_2018_941_35941

Devon Energy_October_2018_941_35941

Devon Energy Corporation

Browse presentations, reports, and documents from Devon Energy Corporation.

Tags

2018

Filter options

All (55)●
brochure (6)○
presentation (48)○
report (1)○

Get the best presentations in your inbox

Join professionals who get a weekly curated collection of top business presentations, investor decks, and industry reports — free.

No spam. Unsubscribe anytime.

Loading viewer...

presentation

Format: PDF presentation

Share:

Devon Energy_October_2018_941_35941 by Devon Energy Corporation.

Browse all presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Devon Energy Corporation

070824-DVN-Presentation_Devon-to-Acquire-Grayson-Mill

presentation

65660efec944e29c3ea3b659_SMU%20Spindletop%20DVN%20Deck%202023

presentation

Similar presentations from other companies

EOG Resources_May_2024_94_101094

presentation

EOG Resources

May_2021_EN_OceanaGoldCorporatePresentation

presentation

Oceana Gold

Devon Energy_October_2018_941_35941 - Devon Energy Corporation | Presentation Nation

Devon Energy_August_2020_960_58960

presentation

Devon Energy_August_2021_805_72805

presentation

Devon Energy_August_2024_155_103155

presentation

Devon Energy_December_2021_411_77411

presentation

thyssenkrupp-nucera_Chlor-Alkali-Technology---the-DNA-for-AWE

presentation

thyssenkrupp Nucera

Ryerson Holding_Q3 2019_826_47826

presentation

Ryerson Holding Corporation

DEVO-1H22-Investor-Presentation-260922

presentation

Dechra Pharmaceuticals

Keryx Biopharmaceuticals_January_2017_230_4230

presentation

Keryx Biopharmaceuticals